Tenaya Reports Positive TN-201 Gene Therapy Data in MYBPC3-Associated HCM
SOUTH SAN FRANCISCO, Calif., June 3, 2026 Tenaya Therapeutics announced new interim data from its ongoing MyPEAK™-1 Phase 1b/2...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., June 3, 2026 Tenaya Therapeutics announced new interim data from its ongoing MyPEAK™-1 Phase 1b/2...
